Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome

The Lancet Neurology

Volumn 12, Issue 8, 2013, Pages 786-798

  Hagerman, Randi ^a   Hagerman, Paul ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR STIMULATING AGENT; ALCOHOL; AMANTADINE; ANTIOXIDANT; BOTULINUM TOXIN A; BUSPIRONE; CALCIUM; CANNABIS; CHOLINESTERASE INHIBITOR; FRAGILE X MENTAL RETARDATION PROTEIN; ILLICIT DRUG; MEMANTINE; MESSENGER RNA; OLIGONUCLEOTIDE; OPIATE; POLYPEPTIDE; PRIMIDONE; RILUZOLE; RNA BINDING PROTEIN; VARENICLINE; VENLAFAXINE;

ALLELE; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYGDALOID NUCLEUS; AMYLOID PLAQUE; ANTERIOR CINGULATE; ATAXIA; ATTENTION; ATTENTION DEFICIT DISORDER; AUTISM; AUTONOMIC DYSFUNCTION; BASAL GANGLION; BASAL METABOLIC RATE; BLOOD BRAIN BARRIER; BRAIN ATROPHY; BRAIN TISSUE; CELL INCLUSION; CEREBELLUM; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL (TOPIC); CORPUS CALLOSUM; DEGENERATIVE DISEASE; DEMENTIA; DEPRESSION; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DROSOPHILA; DYSPHAGIA; ELECTROMYOGRAPHY; ENVIRONMENTAL FACTOR; ERECTILE DYSFUNCTION; ESSENTIAL TREMOR; EVENT RELATED POTENTIAL; EXECUTIVE FUNCTION; FECES INCONTINENCE; FIBROBLAST; FIBROMYALGIA; FRAGILE X ASSOCIATED TREMOR ATAXIA SYNDROME; FRAGILE X SYNDROME; FRONTAL CORTEX; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL REFLUX; GENE MUTATION; GENE SILENCING; HEARING IMPAIRMENT; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; HYPOTHYROIDISM; INSOMNIA; LEYDIG CELL; LIFESPAN; MEMORY; MIDDLE CEREBELLAR PEDUNCLE; MOLECULAR MECHANICS; MUSCLE WEAKNESS; MYOTONIC DYSTROPHY; NERVE CELL DIFFERENTIATION; NERVE DEGENERATION; NEUROIMAGING; NEUROPATHIC PAIN; NEUROPATHOLOGY; NEUROPATHY; NEWBORN SCREENING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; ORTHOSTATIC HYPOTENSION; OXIDATIVE PHOSPHORYLATION; PARIETAL CORTEX; PARKINSONISM; PATHOGENESIS; PENETRANCE; PERIPHERAL NERVOUS SYSTEM; PHENOTYPE; PHYSIOTHERAPY; PREFRONTAL CORTEX; PREMATURE OVARIAN FAILURE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; PURKINJE CELL; REFLEX; REVIEW; SEIZURE; SELECTIVE ATTENTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDERED BREATHING; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS; TRANSCRANIAL MAGNETIC STIMULATION; TREMOR; UPREGULATION; URINARY URGENCY; VERTIGO; WHITE MATTER; WORKING MEMORY;

ATAXIA; FEMALE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HUMANS; MALE; NERVOUS SYSTEM DISEASES; RNA, MESSENGER; TREMOR; TRINUCLEOTIDE REPEAT EXPANSION;

EID: 84880359647     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70125-X     Document Type: Review

References (148)

1. Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000, 66:6-15.
2. Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012, 79:1898-1907.
3. Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001, 57:127-130.
4. Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003, 72:869-878.
5. Juncos JL, Lazarus JT, Graves-Allen E, et al. New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS). Neurogenetics 2011, 12:123-135.
6. Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 1991, 38:269-274.
7. Sullivan SD, Welt C, Sherman S FMR1 and the continuum of primary ovarian insufficiency. Semin Reprod Med 2011, 29:299-307.
8. Franke P, Maier W, Hautzinger M, et al. Fragile-X carrier females: evidence for a distinct psychopathological phenotype?. Am J Med Genet 1996, 64:334-339.
9. Roberts JE, Bailey DB, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009, 150B:130-139.
10. Bourgeois JA, Seritan AL, Casillas EM, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry 2011, 72:175-182.
11. Hessl D, Wang JM, Schneider A, et al. Decreased fragile X mental retardation protein expression underlies amygdala dysfunction in carriers of the fragile X premutation. Biol Psychiatry 2011, 70:859-865.
12. Rodriguez-Revenga L, Madrigal I, Alegret M, Santos M, Mila M Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 2008, 18:153-155.
13. Seritan A, Bourgeois J, Schneider A, Mu Y, Hagerman R, Nguyen DV Ages of onset of mood and anxiety disorders in fragile X premutation carriers. Curr Psychiatr Rev 2013, 9:65-71.
14. First MB, Spitzer RL, Miriam G, Williams JBW Structured clinical interview for DSM-IV-TR axis I disorders, research version, non-patient edition. (SCID-I/NP) 2002, Biometrics Research, New York State Psychiatric Institute, New York.
15. Seltzer MM, Barker ET, Greenberg JS, Hong J, Coe C, Almeida D Differential sensitivity to life stress in FMR1 premutation carrier mothers of children with fragile X syndrome. Health Psychol 2012, 31:612-622.
16. Bailey DB, Raspa M, Bishop E, et al. Health and economic consequences of fragile X syndrome for caregivers. J Dev Behav Pediatr 2012, 33:705-712.
17. Hunter JE, Leslie M, Novak G, et al. Depression and anxiety symptoms among women who carry the FMR1 premutation: impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphisms. Am J Med Genet B Neuropsychiatr Genet 2012, 159B:549-559.
18. Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: characteristic MR imaging findings in adult males with progressive cerebellar and cognitive dysfunction. Am J Neuroradiol 2002, 23:1757-1766.
19. Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007, 69:851-859.
20. Adams PE, Adams JS, Nguyen DV, et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet 2010, 153B:775-785.
21. Loesch DZ, Kotschet K, Trost N, et al. White matter changes in basis pontis in small expansion FMR1 allele carriers with parkinsonism. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:502-506.
22. Toledano-Alhadef H, Basel-Vanagaite L, Magal N, et al. Fragile-X carrier screening and the prevalence of premutation and full-mutation carriers in Israel. Am J Hum Genet 2001, 69:351-360.
23. Fernandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009, 11:324-329.
24. Seltzer MM, Baker MW, Hong J, Maenner M, Greenberg J, Mandel D Prevalence of CGG expansions of the FMR1 gene in a US population-based sample. Am J Med Genet B Neuropsychiatr Genet 2012, 159B:589-597.
25. Tassone F, Long KP, Tong TH, et al. FMR1 CGG allele size and prevalence ascertained through newborn screening in the United States. Genome Med 2012, 4:100.
26. Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2006, 27(2 suppl):S137-S144.
27. Chonchaiya W, Au J, Schneider A, et al. Increased prevalence of seizures in boys who were probands with the FMR1 premutation and co-morbid autism spectrum disorder. Hum Genet 2012, 131:581-589.
28. Tassone F, Hagerman RJ, Taylor AK, et al. Clinical involvement and protein expression in individuals with the FMR1 premutation. Am J Med Genet 2000, 91:144-152.
29. Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet 2003, 121:119-127.
30. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 2007, 37:738-747.
31. Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006, 129(Pt 1):243-255.
32. Tassone F, Adams J, Berry-Kravis EM, et al. CGG repeat length correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet 2007, 144B:566-569.
33. Levenga J, de Vrij FM, Oostra BA, Willemsen R Potential therapeutic interventions for fragile X syndrome. Trends Mol Med 2010, 16:516-527.
34. D'Hulst C, Kooy RF The GABAA receptor: a novel target for treatment of fragile X?. Trends Neurosci 2007, 30:425-431.
35. Cao Z, Hulsizer S, Tassone F, et al. Clustered burst firing in FMR1 premutation hippocampal neurons: amelioration with allopregnanolone. Hum Mol Genet 2012, 21:2923-2935.
36. Conde V, Palomar FJ, Lama MJ, et al. Abnormal GABA-mediated and cerebellar inhibition in women with the fragile X premutation. J Neurophysiol 2013, 109:1315-1322.
37. Bailey DB, Raspa M, Olmsted M, Holiday DB Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008, 146A:2060-2069.
38. Hagerman PJ, Stafstrom CE Origins of epilepsy in fragile X syndrome. Epilepsy Curr 2009, 9:108-112.
39. van Eeghen AM, Pulsifer MB, Merker VL, et al. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol 2013, 55:146-153.
40. Leehey MA, Berry-Kravis E, Min SJ, et al. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord 2007, 22:203-206.
41. Hagerman PJ, Hagerman RJ Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 2004, 10:25-30.
42. Adams PE. The insula sign in male fragile X premutation carriers, both with and without FXTAS. 13th International Fragile X Conference. July 25-29, 2012; Miami, FL, USA.
43. Moris G, Arias M, Lopez MV, Alvarez V Hyperintensity in the basis pontis: atypical neuroradiological findings in a woman with FXTAS. Mov Disord 2010, 25:649-650.
44. Hashimoto R, Javan AK, Tassone F, Hagerman RJ, Rivera SM A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome. Brain 2011, 134(Pt 3):863-878.
45. Hashimoto R, Srivastava S, Tassone F, Hagerman RJ, Rivera SM Diffusion tensor imaging in male premutation carriers of the fragile X mental retardation gene. Mov Disord 2011, 26:1329-1336.
46. Wang JY, Hessl DH, Hagerman RJ, Tassone F, Rivera SM Age-dependent structural connectivity effects in fragile X premutation. Arch Neurol 2012, 69:482-489.
47. Battistella G, Niederhauser J, Fornari E, et al. Brain structure in asymptomatic FMR1 premutation carriers at risk for fragile X-associated tremor/ataxia syndrome. Neurobiol Aging 2013, 34:1700-1707.
48. Hagerman RJ, Coffey SM, Maselli R, et al. Neuropathy as a presenting feature in fragile X-associated tremor/ataxia syndrome. Am J Med Genet A 2007, 143:2256-2260.
49. Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008, 146A:1009-1016.
50. Berry-Kravis E, Goetz CG, Leehey MA, et al. Neuropathic features in fragile X premutation carriers. Am J Med Genet A 2007, 143:19-26.
51. Poston KL, McGovern RA, Goldman JS, Caccappolo E, Mazzoni P Fragile X-associated tremor/ataxia syndrome (FXTAS) with myoclonus. Mov Disord 2010, 25:514-516.
52. Healy DG, Bressman S, Dickson J, et al. Evidence for pre and postsynaptic nigrostriatal dysfunction in the fragile X tremor-ataxia syndrome. Mov Disord 2009, 24:1245-1247.
53. Scaglione C, Ginestroni A, Vella A, et al. MRI and SPECT of midbrain and striatal degeneration in fragile X-associated tremor/ataxia syndrome. J Neurol 2008, 255:144-146.
54. 123I-ioflupane (DaTSCAN) imaging in the fragile X-associated tremor ataxia syndrome (FXTAS): a case report. Neurol Sci 2012, published online Oct 18. 10.1007/s10072-012-1223-6.
55. Hall DA, Howard K, Hagerman R, Leehey MA Parkinsonism in FMR1 premutation carriers may be indistinguishable from Parkinson disease. Parkinsonism Relat Disord 2009, 15:156-159.
56. Sevin M, Kutalik Z, Bergman S, et al. Penetrance of marked cognitive impairment in older male carriers of the FMR1 gene premutation. J Med Genet 2009, 46:818-824.
57. Juncos JL, Lazarus JT, Rohr J, et al. Olfactory dysfunction in fragile X tremor ataxia syndrome. Mov Disord 2012, 27:1556-1559.
58. Hagerman RJ, Hall DA, Coffey S, et al. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging 2008, 3:251-262.
59. Hunsaker MR, Greco CM, Tassone F, et al. Rare intranuclear inclusions in the brains of 3 older adult males with fragile X syndrome: implications for the spectrum of fragile X-associated disorders. J Neuropathol Exp Neurol 2011, 70:462-469.
60. Greco CM, Soontarapornchai K, Wirojanan J, Gould JE, Hagerman PJ, Hagerman RJ Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 2007, 177:1434-1437.
61. Hamlin AA, Sukharev D, Campos L, et al. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet A 2012, 158A:1304-1309.
62. Leehey M, Berry-Kravis E, Goetz C, Hagerman R Clinical neurological phenotype of FXTAS. The fragile-X tremor ataxia syndrome (FXTAS) 2011, 1-16. Springer, New York. F. Tassone, E. Berry-Kravis (Eds.).
63. Soontarapornchai K, Maselli R, Fenton-Farrell G, et al. Abnormal nerve conduction features in fragile X premutation carriers. Arch Neurol 2008, 65:495-498.
64. Chonchaiya W, Tassone F, Ashwood P, et al. Autoimmune disease in mothers with the FMR1 premutation is associated with seizures in their children with fragile X syndrome. Hum Genet 2010, 128:539-548.
65. Hamlin A, Liu Y, Nguyen DV, Tassone F, Zhang L, Hagerman RJ Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet 2011, 156B:923-928.
66. Seritan A, Ortigas M, Seritan S, Bourgeois J, Hagerman R Psychiatric disorders associated with FXTAS. Curr Psychiatry Rev 2013, 9:59-64.
67. Bacalman S, Farzin F, Bourgeois JA, et al. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry 2006, 67:87-94.
68. Winarni TI, Chonchaiya W, Sumekar TA, et al. Immune-mediated disorders among women carriers of fragile X premutation alleles. Am J Med Genet A 2012, 158A:2473-2481.
69. Rodriguez-Revenga L, Madrigal I, Pagonabarraga J, et al. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet 2009, 17:1359-1362.
70. Leehey MA, Legg W, Tassone F, Hagerman R Fibromyalgia in fragile X mental retardation 1 gene premutation carriers. Rheumatology 2011, 50:2233-2236.
71. Behm FG, Gavin IM, Karpenko O, et al. Unique immunologic patterns in fibromyalgia. BMC Clin Pathol 2012, 12:25.
72. Berry-Kravis E, Hall D, Leehey M, Hagerman R Treatment and management of FXTAS. The fragile X-associated tremor ataxia syndrome (FXTAS) 2011, 137-154. Springer, New York. F. Tassone, E. Berry-Kravis (Eds.).
73. Hall D, Tassone F, Klepitskaya O, Leehey M Fragile X-associated tremor ataxia syndrome in FMR1 gray zone allele carriers. Mov Disord 2012, 27:296-300.
74. Grigsby J, Brega AG, Jacquemont S, et al. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci 2006, 248:227-233.
75. Grigsby J, Brega AG, Leehey MA, et al. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Mov Disord 2007, 22:645-650.
76. Grigsby J, Brega AG, Engle K, et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008, 22:48-60.
77. Yang JC, Chan SH, Khan S, et al. Neural substrates of executive dysfunction in Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS): a brain potential study. Cereb Cortex 2012, published online Aug 23. 10.1093/cercor/bhs251.
78. Cornish KM, Kogan CS, Li L, Turk J, Jacquemont S, Hagerman RJ Lifespan changes in working memory in fragile X premutation males. Brain Cogn 2009, 69:551-558.
79. Hunter JE, Epstein MP, Tinker SW, Abramowitz A, Sherman SL The FMR1 premutation and attention-deficit hyperactivity disorder (ADHD): evidence for a complex inheritance. Behav Genet 2012, 42:415-422.
80. Hunter JE, Allen EG, Abramowitz A, et al. No evidence for a difference in neuropsychological profile among carriers and noncarriers of the FMR1 premutation in adults under the age of 50. Am J Hum Genet 2008, 83:692-702.
81. Moore CJ, Daly EM, Schmitz N, et al. A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia 2004, 42:1934-1947.
82. Brega AG, Reynolds A, Bennett RE, et al. Functional status of men with the fragile X premutation, with and without the tremor/ataxia syndrome (FXTAS). Int J Geriatr Psychiatry 2009, 24:1101-1109.
83. Hashimoto R, Backer KC, Tassone F, Hagerman RJ, Rivera SM An fMRI study of the prefrontal activity during the performance of a working memory task in premutation carriers of the fragile X mental retardation 1 gene with and without fragile X-associated tremor/ataxia syndrome (FXTAS). J Psychiatr Res 2011, 45:36-43.
84. Seritan AL, Nguyen DV, Farias ST, et al. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 2008, 147B:1138-1144.
85. Tassone F, Greco CM, Hunsaker MR, et al. Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav 2012, 11:577-585.
86. Renoux AJ, Todd PK Neurodegeneration the RNA way. Prog Neurobiol 2012, 97:173-189.
87. Li Y, Jin P RNA-mediated neurodegeneration in fragile X-associated tremor/ataxia syndrome. Brain Res 2012, 1462:112-117.
88. Hagerman PJ Current gaps in understanding the molecular basis of FXTAS. Tremor Other Hyperkinet Mov (NY) 2012, 2.
89. Echeverria GV, Cooper TA RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res 2012, 1462:100-111.
90. Udd B, Krahe R The myotonic dystrophies: molecular, clinical, and therapeutic challenges. Lancet Neurol 2012, 11:891-905.
91. Iwahashi CK, Yasui DH, An HJ, et al. Protein composition of the intranuclear inclusions of FXTAS. Brain 2006, 129:256-271.
92. Sofola OA, Jin P, Qin Y, et al. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a Drosophila model of FXTAS. Neuron 2007, 55:565-571.
93. Jin P, Duan R, Qurashi A, et al. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor/ataxia syndrome. Neuron 2007, 55:556-564.
94. Aumiller V, Graebsch A, Kremmer E, Niessing D, Forstemann K Drosophila Pur-alpha binds to trinucleotide-repeat containing cellular RNAs and translocates to the early oocyte. RNA Biol 2012, 9:633-643.
95. Sellier C, Rau F, Liu Y, et al. Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients. Embo J 2010, 29:1248-1261.
96. Disney MD, Liu B, Yang WY, et al. A small molecule that targets r(CGG)(exp) and improves defects in fragile X-associated tremor ataxia syndrome. ACS Chem Biol 2012, 7:1711-1718.
97. Sellier C, Freyermuth F, Tabet R, et al. Sequestration of DROSHA and DGCR8 by expanded CGG RNA repeats alters microRNA processing in fragile X-associated tremor/ataxia syndrome. Cell Rep 2013, 3:869-880.
98. Galloway JN, Nelson DL Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome. Future Neurol 2009, 4:785.
99. Tan H, Qurashi A, Poidevin M, Nelson DL, Li H, Jin P Retrotransposon activation contributes to fragile X premutation rCGG-mediated neurodegeneration. Hum Mol Genet 2012, 21:57-65.
100. Tan H, Poidevin M, Li H, Chen D, Jin P MicroRNA-277 modulates the neurodegeneration caused by Fragile X premutation rCGG repeats. PLoS Genet 2012, 8:e1002681.
101. Muslimov IA, Patel MV, Rose A, Tiedge H Spatial code recognition in neuronal RNA targeting: role of RNA-hnRNP A2 interactions. J Cell Biol 2011, 194:441-457.
102. Ash PE, Bieniek KF, Gendron TF, et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77:639-646.
103. Taylor JP Neuroscience. RNA that gets RAN in neurodegeneration. Science 2013, 339:1282-1283.
104. Todd PK, Oh SY, Krans A, et al. CGG repeat-associated translation mediates neurodegeneration in fragile X tremor ataxia syndrome. Neuron 2013, 78:440-455.
105. Entezam A, Biacsi R, Orrison B, et al. Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model. Gene 2007, 395:125-134.
106. Napoli E, Ross-Inta C, Wong S, et al. Altered zinc transport disrupts mitochondrial protein processing/import in fragile X-associated tremor/ataxia syndrome. Hum Mol Genet 2011, 20:3079-3092.
107. Ross-Inta C, Omanska-Klusek A, Wong S, et al. Evidence of mitochondrial dysfunction in fragile X-associated tremor/ataxia syndrome. Biochem J 2010, 429:545-552.
108. Kaplan ES, Cao Z, Hulsizer S, et al. Early mitochondrial abnormalities in hippocampal neurons cultured from Fmr1 pre-mutation mouse model. J Neurochem 2012, 123:613-621.
109. Qurashi A, Li W, Zhou JY, Peng J, Jin P Nuclear accumulation of stress response mRNAs contributes to the neurodegeneration caused by fragile X premutation rCGG repeats. PLoS Genet 2011, 7:e1002102.
110. Zhang L, Coffey S, Lua LL, et al. FMR1 premutation in females diagnosed with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80:812-814.
111. Greco CM, Tassone F, Garcia-Arocena D, et al. Clinical and neuropathologic findings in a woman with the FMR1 premutation and multiple sclerosis. Arch Neurol 2008, 65:1114-1116.
112. Chen Y, Tassone F, Berman RF, et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 2010, 19:196-208.
113. Paul R, Pessah IN, Gane L, et al. Early onset of neurological symptoms in fragile X premutation carriers exposed to neurotoxins. Neurotoxicology 2010, 31:399-402.
114. Hudson AE, Hemmings HC Are anaesthetics toxic to the brain?. Br J Anaesth 2011, 107:30-37.
115. O'Dwyer JP, Clabby C, Crown J, Barton DE, Hutchinson M Fragile X-associated tremor/ataxia syndrome presenting in a woman after chemotherapy. Neurology 2005, 65:331-332.
116. King OD, Gitler AD, Shorter J The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease. Brain Res 2012, 1462:61-80.
117. Hashem V, Galloway JN, Mori M, et al. Ectopic expression of CGG containing mRNA is neurotoxic in mammals. Hum Mol Genet 2009, 18:2443-2451.
118. Greco CM, Hagerman RJ, Tassone F, et al. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 2002, 125:1760-1771.
119. Tassone F, Iwahashi C, Hagerman PJ FMR1 RNA within the intranuclear inclusions of fragile X-associated tremor/ataxia syndrome (FXTAS). RNA Biol 2004, 1:103-105.
120. Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008, 70:1397-1402.
121. Gokden M, Al-Hinti JT, Harik SI Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology 2009, 29:280-284.
122. Hunsaker MR, Greco CM, Spath MA, et al. Widespread non-central nervous system organ pathology in fragile X premutation carriers with fragile X-associated tremor/ataxia syndrome and CGG knock-in mice. Acta Neuropathol 2011, 122:467-479.
123. Garcia-Arocena D, Yang JE, Brouwer JR, et al. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet 2010, 19:299-312.
124. Al-Hinti JT, Nagan N, Harik SI Fragile X premutation in a woman with cognitive impairment, tremor, and history of premature ovarian failure. Alzheimer Dis Assoc Disord 2007, 21:262-264.
125. Karmon Y, Gadoth N Fragile X associated tremor/ataxia syndrome (FXTAS) with dementia in a female harbouring FMR1 premutation. J Neurol Neurosurg Psychiatry 2008, 79:738-739.
126. Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004, 291:460-469.
127. Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004, 74:1051-1056.
128. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: clinical features, genetics, and testing guidelines. Mov Disord 2007, 22:2018-2030.
129. Geibprasert S, Gallucci M, Krings T Addictive illegal drugs: structural neuroimaging. Am J Neuroradiol 2010, 31:803-808.
130. Bora E, Yucel M, Fornito A, et al. White matter microstructure in opiate addiction. Addict Biol 2012, 17:141-148.
131. Arnone D, Abou-Saleh MT, Barrick TR Diffusion tensor imaging of the corpus callosum in addiction. Neuropsychobiology 2006, 54:107-113.
132. Zalesky A, Solowij N, Yucel M, et al. Effect of long-term cannabis use on axonal fibre connectivity. Brain 2012, 135:2245-2255.
133. Maillard P, Seshadri S, Beiser A, et al. Effects of systolic blood pressure on white-matter integrity in young adults in the Framingham Heart Study: a cross-sectional study. Lancet Neurol 2012, 11:1039-1047.
134. Hall DA, Berry-Kravis E, Hagerman RJ, Hagerman PJ, Rice CD, Leehey MA Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord 2006, 21:1741-1744.
135. Gane L, Howard K Genetic counseling for FXTAS and FMR1-associated disorders. The fragile X-associated tremor ataxia syndrome (FXTAS) 2011, 155-176. Springer, New York. F. Tassone, E. Berry-Kravis (Eds.).
136. Iosif A-M, Sciolla AF, Brahmbhatt K, Seritan AL Caregiver burden in fragile X families. Curr Psychiatry Rev 2013, 9:85-91.
137. Richard E, Reitz C, Honig L, et al. Late-life depression, mild cognitive impairment, and dementia. JAMA Neurol 2013, 70:383-389.
138. Ferrara JM, Adam OR, Ondo WG Treatment of fragile-X-associated tremor/ataxia syndrome with deep brain stimulation. Mov Disord 2009, 24:149-151.
139. Hagerman RJ, Pak JS, Ortigas M, et al. Case series: deep brain stimulation in patients with FXTAS. Brain Disord Therapy 2012, 1:104.
140. Ristori G, Romano S, Visconti A, et al. Riluzole in cerebellar ataxia: a randomized, double-blind, placebo-controlled pilot trial. Neurology 2010, 74:839-845.
141. Ortigas MC, Bourgeois JA, Schneider A, et al. Improving fragile X-associated tremor/ataxia syndrome symptoms with memantine and venlafaxine. J Clin Psychopharmacol 2010, 30:642-644.
142. Hagerman R, Lauterborn J, Au J, Berry-Kravis E Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 2012, 54:297-335.
143. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. Sci Transl Med 2012, 4:152ra27.
144. Lee JE, Bennett CF, Cooper TA RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1. Proc Natl Acad Sci USA 2012, 109:4221-4226.
145. Cornish KM, Hocking DR, Moss SA, Kogan CS Selective executive markers of at-risk profiles associated with the fragile X premutation. Neurology 2011, 77:618-622.
146. Loesch DZ, Sherwell S, Kinsella G, et al. Fragile X-associated tremor/ataxia phenotype in a male carrier of unmethylated full mutation in the FMR1 gene. Clin Genet 2012, 82:88-92.
147. Tassone F, Hagerman RJ, Taylor AK, Hagerman PJ A majority of fragile X males with methylated, full mutation alleles have significant levels of FMR1 messenger RNA. J Med Genet 2001, 38:453-456.
148. Liu Y, Winarni T, Zhang L, Tassone F, Hagerman R Fragile X-associated tremor/ataxia syndrome (FXTAS) in grey zone carriers. Clin Genet 2013, 84:74-77.